Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Technical Presentation (November 2024)
13 slides from Tempus Ai's technical presentation, November 2024
Slide 1: Integrated Transcriptomic Analysis of CIC::DUX4 Fusion Sarcomas Reveals Elevated Proliferation Signaling and Implicates DNA Repair Gene POLE
INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE 1,2 1 1 Nathan D. Seligson , Anjali Paragji , Feha Shahalam , Binyam 3 3,4 Yilma , James L. Chen 1. Department of Pharmacotherapy and Translational Research, T
Slide 2: Disclosures
Disclosures I report no financial conflicts of interest Presented by: 2024 Nathan Seligson Content of this presentation is the property of the author, ANNUAL MEETING licensed by CTOS. Permission is required to reuse. University of Florida, Nemours Children’s Health
Slide 3: Introduction
Introduction EwS • CIC::DUX4 translocation positive sarcomas (CDS) CDS • Aggressive, chemoresistant • Overall survival for patients with CDS is worse than other small blue Antonescu, C. R. et al. Am J Surg Pathol 41, 941-949 (2017). round cell tumors (SBRCT) • Limited knowledge about the molecular l
Slide 4: Introduction
Introduction • We previously reported that SBRCTs demonstrate unique molecular signatures at the DNA and RNA level • Defining driver translocation correlates with unique molecular signals • Molecular signals may be targetable or clinically actionable • Using a similar methodology, we conduct an inte
Slide 5: Genomic Landscape of CDS
Demographics (DNA Analysis) Genomic Landscape of CDS Age [Median (IQR)]; Years ≤18 Yeas 28.5 (18.0-37.8) 12 (30.8%) Not Reported 2 (5.1%) Sex Female 24 (61.5%) Male 15 (38.5%) Tumor Purity (Median [IQR]) 51% [29.5-72.5%] Not Reported 13 (33.3%) Tumor Mutation Burden Median [IQR]; Mutations/Mb 0.8 [0
Slide 6: CDS Presents A "Quiet Genome"
CDS Presents A “Quiet Genome” Presented by: 2024 Nathan Seligson Content of this presentation is the property of the author, ANNUAL MEETING licensed by CTOS. Permission is required to reuse. University of Florida, Nemours Children’s Health
Slide 7: CDS Gene Signature Development
CDS Gene Signature Development 4,347 Genes 9 Genes 5 Genes ETV1/4/5, DUSP4, POLE Presented by: 2024 Nathan Seligson Content of this presentation is the property of the author, ANNUAL MEETING licensed by CTOS. Permission is required to reuse. University of Florida, Nemours Children’s Health
Slide 8: CDS Signature Validation
CDS Signature Validation Presented by: 2024 Nathan Seligson Content of this presentation is the property of the author, ANNUAL MEETING licensed by CTOS. Permission is required to reuse. University of Florida, Nemours Children’s Health
Slide 9: Global DNA Repair Upregulated in CDS
Global DNA Repair Upregulated in CDS Elevated POLE expression has not yet been reported in CDS POLE is associated with DNA repair • Typically de-activated in cancer Reactome database to test expression of DNA repair pathways in CDS Presented by: 2024 Nathan Seligson Content of this presentation is t
Slide 10: DNA Repair and Proliferation
DNA Repair and Proliferation Given the high proliferation rate of CDS we further investigated the correlation between POLE and cellular proliferation (MKI67) • + correlation across cancers • + correlation in CDS samples alone (r2=0.54, p=0.0002) Presented by: 2024 Nathan Seligson Content of this pre
Slide 11: Conclusion
Conclusion Presented by: 2024 Nathan Seligson Content of this presentation is the property of the author, ANNUAL MEETING licensed by CTOS. Permission is required to reuse. University of Florida, Nemours Children’s Health
Slide 12: Conclusion
Conclusion CIC::DUX4 sarcomas are molecularly distinct from other SBRCT 5-gene gene signature, including POLE, is strongly associated with the fusion • POLE has heretofore not been reported in CDS • Clear markers of proliferation are seen recapitulating prior work Additional clinical studies are nee
Slide 13: Thank You
Thank You Seligson Lab Anjali Paragji Feha Shahalam Funding University of Florida Acknowledgements This research is conducted with special thanks to the Derek Jahn Beat Sarcoma Foundation. Derek’s memory will live on. Presented by: 2024 Nathan Seligson Content of this presentation is the property of